Kissei Pharmaceutical Co (TSE:4547) Net Income From Continuing Operations : 円11,290 Mil (TTM As of Dec. 2023)

View and export this data going back to 1988. Start your Free Trial

What is Kissei Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Kissei Pharmaceutical Co's net income from continuing operations for the three months ended in Dec. 2023 was 円2,695 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was 円11,290 Mil.

Kissei Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Kissei Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kissei Pharmaceutical Co Net Income From Continuing Operations Chart

Kissei Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Net Income From Continuing Operations

Get a 7-Day Free Trial

4,630.00

7,476.00

16,507.00

13,680.00

14,449.00

Kissei Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															3,890.00	3,324.00	2,433.00	2,695.00	2,838.00

Kissei Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円11,290 Mil.

Kissei Pharmaceutical Co (TSE:4547) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kissei Pharmaceutical Co Ltd (TSE:4547) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

KSPHF:USA

Address

19-48, Yoshino, Matsumoto City, Nagano, JPN, 399-8710

Website

http://www.kissei.co.jp

Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company's operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kissei Pharmaceutical Co (TSE:4547) Headlines

No Headlines